We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

456 hedge funds and large institutions have $6.17B invested in Bio-Rad Laboratories Class A in 2024 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 148 increasing their positions, 147 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 56

32% more call options, than puts

Call options by funds: $5.22M | Put options by funds: $3.94M

4% more funds holding

Funds holding: 437456 (+19)

1% more repeat investments, than reductions

Existing positions increased: 148 | Existing positions reduced: 147

3.24% less ownership

Funds ownership: 85.21%81.97% (-3.2%)

5% less capital invested

Capital invested by funds: $6.5B → $6.17B (-$329M)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
456
Holders Change
+19
Holders Change %
+4.35%
% of All Funds
6.01%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
81
Increased
148
Reduced
147
Closed
56
Calls
$5.22M
Puts
$3.94M
Net Calls
+$1.28M
Net Calls Change
-$631K
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$15.5M -$2.37M -6,988 -13%
Balyasny Asset Management
52
Balyasny Asset Management
Illinois
$15.5M +$16M +47,073 New
FGP
53
Freestone Grove Partners
California
$15.1M +$15.6M +46,015 New
Natixis Advisors
54
Natixis Advisors
Massachusetts
$15M +$1.49M +4,390 +11%
MCM
55
Moore Capital Management
New York
$14.8M
CIBC Private Wealth Group
56
CIBC Private Wealth Group
Georgia
$14.5M -$422K -1,243 -3%
Principal Financial Group
57
Principal Financial Group
Iowa
$14.5M -$79.4K -234 -0.5%
Grantham, Mayo, Van Otterloo & Co (GMO)
58
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$14.1M -$13.6M -40,015 -48%
Acadian Asset Management
59
Acadian Asset Management
Massachusetts
$13.4M +$13.3M +39,099 +2,175%
Barclays
60
Barclays
United Kingdom
$13.3M -$528K -1,557 -4%
Wells Fargo
61
Wells Fargo
California
$13.3M -$823K -2,426 -6%
GF
62
Gabelli Funds
New York
$13.2M
N
63
Nuveen
North Carolina
$13M +$111K +327 +0.8%
KCM
64
Kornitzer Capital Management
Kansas
$12.9M +$267K +786 +2%
Invesco
65
Invesco
Georgia
$12.8M -$464K -1,368 -3%
WHG
66
Westwood Holdings Group
Texas
$12.6M -$339 -1 -0%
Deutsche Bank
67
Deutsche Bank
Germany
$12.4M +$349K +1,027 +3%
Arrowstreet Capital
68
Arrowstreet Capital
Massachusetts
$12.1M +$10.1M +29,707 +410%
Sumitomo Mitsui Trust Group
69
Sumitomo Mitsui Trust Group
Japan
$12M -$533K -1,569 -4%
Ameriprise
70
Ameriprise
Minnesota
$11.2M +$194K +571 +2%
CS
71
Candriam SCA
Luxembourg
$11.1M +$754K +2,220 +7%
BG
72
Bellevue Group
Switzerland
$11M -$4.28M -12,600 -27%
California Public Employees Retirement System
73
California Public Employees Retirement System
California
$10.6M +$356K +1,048 +3%
PCM
74
Portolan Capital Management
Massachusetts
$10M +$2.95M +8,686 +40%
AQR Capital Management
75
AQR Capital Management
Connecticut
$9.65M -$389K -1,147 -4%

BIO Hedge Fund Activity: Q4 2024 in Review

456 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2024, worth a combined $6.17B — down 5.1% from $6.5B a quarter earlier.

Buyers outnumbered sellers: 81 funds opened new BIO positions and 56 closed out — a net gain of 25 holders — while 148 added to existing stakes and 147 trimmed.

The largest buyer was Ariel Investments, adding an estimated $61.7M. The largest seller was VanEck Associates, cutting an estimated $197M.

  • 456 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2024, up from 437 in Q3 2024.
  • Funds reported $6.17B of Bio-Rad Laboratories Class A stock for Q4 2024, down 5.1% quarter-over-quarter.
  • 81 funds opened new Bio-Rad Laboratories Class A positions in Q4 2024 and 56 closed out, a net change of +25 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q4 2024 was Ariel Investments, an estimated $61.7M added.
  • The largest Bio-Rad Laboratories Class A seller in Q4 2024 was VanEck Associates, an estimated $197M sold.

Based on aggregated 13F filings for Q4 2024.